文献速递乳腺癌放疗

新辅助化疗后腋窝淋巴结阳性乳腺癌患者乳房切除术后放疗的使用率与生存趋势

Postmastectomy Radiation in Breast Cancer Patients With Pathologically Positive Lymph Nodes After Neoadjuvant Chemotherapy: Usage Rates and Survival Trends.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-06-28

该研究基于美国国家癌症数据库分析2004至2013年接受新辅助化疗后行乳房切除且病理学淋巴结阳性的非转移性乳腺癌患者,共纳入29270例,其中62.5%接受了乳房切除术后放疗(PMRT)。ypN3患者接受PMRT的5年总生存率显著更高(66% vs 63%;P=.042),多变量分析显示PMRT仅与ypN3患者生存改善相关(HR 0.85;95%CI 0.74-0.97)。

要点

  • 新辅助化疗后淋巴结阳性乳腺癌患者中PMRT使用率为62.5%,ypN2和ypN3亚组使用率分别为68.4%和67.0%。
  • ypN3患者接受PMRT者5年总生存率显著高于未接受者(66% vs 63%;P=.042)。
  • 多变量分析中PMRT仅与ypN3患者生存改善独立相关(HR 0.85;95%CI 0.74-0.97)。

核心结论

  • 相当部分新辅助化疗后晚期残留淋巴结病变的乳腺癌患者未接受适当的辅助放疗。
  • ypN3疾病患者可能从PMRT中获得生存获益。
  • 全国PMRT实践模式存在社会经济差异。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库识别2004至2013年诊断的非转移性乳腺癌女性。
  • 纳入接受新辅助化疗后行乳房切除且宏观病理学淋巴结阳性的患者,共29270例。
  • 采用Joinpoint回归模型评估PMRT年度使用趋势,多变量回归模型识别与PMRT使用相关的因素,时间依赖Cox模型评估死亡预测因素。

主要发现

  • 29270例患者中62.5%接受了PMRT。
  • PMRT在所有淋巴结亚组中均明显使用不足,尤其是ypN2(68.4%)和ypN3(67.0%)患者。
  • 西班牙裔患者及持有Medicaid或Medicare保险者接受PMRT的可能性低于非西班牙裔及其他保险类型患者。
  • ypN1和ypN2患者无论是否接受PMRT,调整后5年OS率相似;ypN3患者接受PMRT者5年OS率显著更高(66% vs 63%;P=.042)。
  • 多变量分析中,调整患者、机构和肿瘤变量后,PMRT仅与ypN3患者生存改善相关(多变量风险比0.85;95%置信区间0.74-0.97)。

关键数值与推荐

  • ypN3患者接受PMRT者5年OS率为66%,未接受者为63%(P=.042)。
  • ypN3患者PMRT与生存改善的多变量风险比为0.85(95%CI 0.74-0.97)。
  • ypN2患者PMRT使用率为68.4%,ypN3患者为67.0%。

临床怎么用

  • 对新辅助化疗后乳房切除且病理学淋巴结阳性的乳腺癌患者,应评估PMRT指征,尤其ypN3患者可能获益。
  • 需关注西班牙裔及Medicaid/Medicare保险患者中PMRT使用不足的差异并针对性改进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze postmastectomy radiation therapy (PMRT) usage and its association with overall survival (OS) in breast cancer patients with pathologically positive lymph nodes after neoadjuvant chemotherapy (NAC). METHODS AND MATERIALS: Using the National Cancer Database, we identified women with nonmetastatic breast cancer diagnosed from 2004 to 2013 who had received NAC and undergone mastectomy with macroscopic pathologically positive lymph nodes. Joinpoint regression models were used to assess temporal trends in annual PMRT usage. Multivariable regression models were used to identify factors associated with PMRT use. A time-dependent Cox model was used to evaluate the predictors of mortality. RESULTS: The study included 29,270 patients, of whom 62.5% received PMRT. PMRT was markedly underused among all nodal subgroups, in particular, among ypN2 (68.4%) and ypN3 (67.0%) patients. Hispanic patients and those with Medicaid or Medicare insurance were less likely to receive PMRT than were non-Hispanics and patients with other insurance carriers. The adjusted 5-year OS rates were similar in ypN1 and ypN2 patients with or without PMRT but were significantly greater in ypN3 patients receiving PMRT (66% vs 63%; P=.042). On multivariable analysis, PMRT was associated with improved survival only among ypN3 patients after adjusting for patient, facility, and tumor variables (multivariable hazard ratio 0.85; 95% confidence interval 0.74-0.97). CONCLUSIONS: A considerable portion of breast cancer patients with advanced residual nodal disease after NAC did not receive appropriate adjuvant radiation. We also found socioeconomic disparities in national PMRT practice patterns. Patients with ypN3 disease might derive a survival benefit from PMRT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ohri N, Moshier E, Ho A, et al. Postmastectomy Radiation in Breast Cancer Patients With Pathologically Positive Lymph Nodes After Neoadjuvant Chemotherapy: Usage Rates and Survival Trends. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280449. doi:10.1016/j.ijrobp.2017.06.2458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。